

Date: 5th August, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Press Release on the Unaudited Financial Results for the quarter ended 30th June, 2025.

With reference to the captioned subject, please find enclosed herewith Press Release on the Unaudited Financial Results for the quarter ended 30th June, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Press Release

**Alembic Pharmaceuticals Ltd announces financial results for Q1 FY26
Profit After Tax at Rs. 154 Cr up by 15%**

Vadodara, August 5th, 2025

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June 2025.

Financial Highlights

- Revenue increased by 10% to Rs.1,711 Cr.
- EBITDA up by 20% to Rs. 288 Cr.
- EBITDA Margin at 17% of Revenue
- Profit Before Tax up by 21% to Rs.191 Cr.
- Net Profit at Rs.154 Cr. up by 15%.

Commenting on the results, Mr. Pranav Amin MD, Alembic Pharmaceuticals Limited, said, we began FY26 on a strong note, delivering revenue growth across all businesses. The growth was driven by a 21% increase in RoW markets, reflecting our strategic expansion and disciplined execution across geographies. Despite ongoing pricing pressure, our US business grew by 13%, supported by volume gains. As we ramp up utilization of our new manufacturing facilities and continue to drive cost optimization initiatives, we expect to benefit from improved operating leverage.

Operational Highlights

India Branded Business

- India Branded Business delivered a 5% YoY growth, reaching ₹599 Cr in revenue for the quarter.
- Good momentum in Specialty Therapies with Gynaecology, Cardiology, Anti-Diabetic, Ophthalmology and Animal healthcare segments demonstrating healthy growth.
- Anti-infective and Cough & Cold segments grew in line with represented market performance, with robust operational execution.
- Successfully introduced 3 new products during the quarter.

International Business

- US Generics grew by 13% to Rs. 523 Cr. for the quarter.
- 4 Launches in the US market during the quarter.
- Ex-US International Generics grew by 21% to Rs. 328 Cr. for the quarter.
- 6 ANDA approvals received during the quarter, 223 Cumulative ANDA approvals.

ALEMBIC PHARMACEUTICALS LIMITED

API Business

- API business grew by 1% to Rs. 261 Cr. for the quarter.

The summary of Total Revenue is as under:

(Rs in Cr.)

Particulars	Q1 FY26	Q1 FY25	% Change
Formulation			
India	599	572	5%
USA	523	461	13%
Ex- US	328	271	21%
API	261	259	1%
Total	1,711	1,562	10%

Earnings Call: Alembic Pharmaceuticals Limited will host an investor call at 4:30 pm IST on August 5, 2025, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1411/ +91 22 7115 8312. Other toll numbers are listed in the conference call invitation, which is posted on the Company website www.alembicpharmaceuticals.com. The operator will provide instructions on asking questions before the start of the call.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India.

Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information, contact:

Ajay Kumar Desai: Phone: +91 022- 66953681 Email: ajay.desai@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123